HRSA Newborn Screening Implementation Program - Conditions Added to Recommended Uniform Screening Panel (RUSP)

Sponsor Deadline: 

May 27, 2016

Internal Deadline: 

Apr 29, 2016


Health Resources and Services Admin

url to HRSA

Limited to one application per institution

The Health Resources and Services Administration HRSA is the primary Federal agency for improving access to health care by strengthening the health care workforce, building healthy communities and achieving health equity.  
HRSA grants improve and expand health care services for underserved people, focusing on the following program areas:  Health Professions, HIV/AIDS, Maternal & Child Health, Office of the Administrator, Primary Health Care/Health Centers, Rural Health, Healthcare Systems, Organ Donation, and Clinician Recruitment. 
HRSA opportunities is external)

HRSA solicitations generally limit the number of applications that may go forward in response to a specific solicitation.  If you wish to apply to a program that limits the number of applications allowed per institution, please convey your interest by emailing a one-page abstract about your proposal to sends e-mail)   in the Office of the Vice President for Research and Economic Development with a cc to the Division of Sponsored Programs DSP sends e-mail)  or sends e-mail) as soon as possible, but at least 30 days in advance of the deadline.  If we receive multiple abstracts in response to a given solicitation, a review will be conducted to select the applicant to submit on behalf of the University of Iowa.  Application materials are due in DSP at least 5 business days prior to the deadline.

The overall goal for this initiative is to increase the number of newborns receiving early treatment for Pompe disease, Mucopolysaccharidosis I (MPS I), and X-linked Adrenoleukodystrophy (X-ALD) by: fostering the integration of and building capacity for newborn screening for these conditions; increasing the number of NBS laboratory scientists and short-term follow-up personnel with knowledge and skill in conducting newborn screening and short-term follow-up for Pompe disease, MPS 1, and X-ALD; providing training, education, and sharing of information via a national meeting for the public health community; supporting primary health care providers through education and resources, with special attention to cases with later onset of symptoms; and engaging families in the development and dissemination of educational materials and support mechanisms that are culturally sensitive and family-centric for families who have an infant identified through NBS.